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According to the most recent set of consensus guidelines from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, a truncating variant is expected to be pathogenic only when the known disease mechanism is loss of function. 4 Therefore, the novel RYR1 truncating variant could be reclassified as "uncertain significance" rather than pathogenic or likely pathogenic.
Dr Biesecker 1 also indicates that the pathogenicity of a known MUTYH truncating variant, c.799C>T (p.Gln267*), should be reconsidered. We agree that the variant is listed by the Human Gene Mutation Database (HGMD) as "DM?" and that the primary paper describes that variant as being pathogenic in trans with another MUTYH variant. 5 However, the definition of "DM?" in the HGMD suggests that the mutation is likely disease-causing (likely pathogenic). Interestingly, MUTYH p.Gln454Pro, the variant concurrently observed in the same individual in the primary article describing this mutation, is listed by the HGMD as "DM" (not "DM?") without any additional evidence. For a given MUTYH p.Gln267* variant, we can collect at least two pieces of evidence for pathogenicity, including the null variant and extremely low allele frequency. The variant could be classified as likely pathogenic according to the scoring rules of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology guidelines for sequence interpretation. 4 In addition, MUTYH pathogenic or likely pathogenic variants in our report were excluded from the estimation of the frequency of secondary findings because they were found in individuals who carry only one copy of the variant, causing recessive disease.
Classification of sequence variants to the appropriate category is very difficult. As the clinical use of exome or genome sequencing continues to rapidly increase, the importance of identification and reporting of secondary findings will be further emphasized. We believe that, although several limitations and weaknesses exist, our data provide evidence to support the genomic study of secondary findings in Korea. To improve the accuracy and consistency of variant classification, we must put in place stringent standards and guidelines and perform independent consensus reviews because there will always be the possibility of erroneous interpretation.
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